
Exhibit 10.1 [***] = Certain confidential information  {E1 contained}  in this document,  {E2 marked}  by brackets, has been  {E3 omitted}  because it is both (i) not material and (ii) would likely be competitively harmful if publicly  {E4 disclosed}  . Miltenyi Biotec-Bellicum Supply Agreement (Execution Copy  March 27, 2019 )

SUPPLY AGREEMENT

(MB Global Contract Number MBGCR 19001)

This Supply Agreement (this "Agreement") is  {E5 made}  and  {E6 entered}  into, effective as of  March 27, 2019  (the "Effective  Date  "), by and between Miltenyi Biotec GmbH, a German corporation  {E7 having}  an address at Friedrich-Ebert-Str. 68, 51429 Bergisch Gladbach, Germany (hereinafter  {E8 referred}  to as "Miltenyi"), and Bellicum Pharmaceuticals, Inc., a US corporation,  {E9 having}  a  {E10 registered}  office at  2130  West Holcombe Boulevard, Suite 800, Houston, TX 77030 (on behalf of itself and its Affiliates, individually and collectively  {E11 referred}  to as "Bellicum"). Miltenyi and Bellicum are sometimes  {E12 referred}  to herein individually as a "Party" and collectively as the "Parties."

RECITALS

WHEREAS, Miltenyi is a biotechnology company  {E13 having}  technology and expertise  {E14 relating}  to, inter alia, monoclonal antibodies, cell {E143 separation}, and cell and gene {E144 therapy}, and Miltenyi has  {E15 developed}  and  {E16 owns}  and  {E17 controls}  various platform technologies for {E56 use} in research and clinical applications and pharmaceutical {E48 development} and {E49 manufacturing},  {E18 including}  (i) systems, devices, reagents, disposables and related procedures and protocols for cell {E139 processing} ( {E19 including}  cell {E50 enrichment}, {E51 purification}, {E52 activation}, {E53 modification} and {E54 expansion}) and cell {E55 analysis}, (ii) bioassay reagents, assays, probes and related materials, and (iii) clinical cell or sample processing systems;

WHEREAS, Bellicum is a clinical stage biopharmaceutical company  {E20 focused}  on  {E21 discovering}  and  {E22 developing}  cellular immunotherapies for hematological cancers and solid tumors, as well as orphan  {E23 inherited}  blood diseases;

WHEREAS, Bellicum desires to  {E24 use}  certain Miltenyi Products (as  {E25 defined}  below) solely for the Permitted {E57 Use} (as  {E26 defined}  below) in connection with the {E58 development} and {E59 manufacture} of certain Bellicum Products (as  {E27 defined}  below) by Bellicum and/or its Subcontractors or Licensees (as  {E28 defined}  below) for {E140 use} in preclinical and clinical development {E60 programs} and, if  {E29 approved}  , for commercial {E61 use}; and

WHEREAS, Miltenyi desires to  {E30 sell}  to Bellicum, and Bellicum desires to  {E31 purchase}  from Miltenyi, the Miltenyi Products in accordance with the terms and conditions set forth in this Agreement. NOW, THEREFORE, in consideration of the foregoing and the mutual covenants  {E32 contained}  herein, the Parties  {E33 agree}  as  follows  :

Article 1 DEFINITIONS AND INTERPRETATION

1.1 Definitions. For the purposes of this Agreement, unless the context  {E34 requires}  otherwise, the  {E35 following}  terms shall have the meanings set forth below:

"Additional Countries" shall have the meaning set forth in Section 2.3 of this Agreement. "Affiliate" means, with respect to a Party, any corporation, association, or other entity which, directly or indirectly, controls the Party or is controlled by the Party or is under common control with such Party, where "control" means the possession, directly or indirectly, of the power to direct or cause the direction of the {E62 affairs} or {E63 management} of a corporation, association, or other entity through the ownership of fifty percent





Miltenyi Biotec-Bellicum Supply Agreement (Execution Copy,  March 27, 2019 )

or more of the voting securities or otherwise,  {E36 including}   {E37 having}  the power to  {E38 elect}  a majority of the board of directors or other  {E39 governing}  body of such corporation, association, or other entity. "Agreed Standards" means all standards, specifications, guidelines and regulations as to quality, safety and {E64 performance} as are consistently applied by Miltenyi from time to time with respect to the manufacture and quality control of the relevant Miltenyi Product in accordance with Miltenyi's established quality system, standard operating procedures, and quality control procedures, and includes (i) any standard(s) as may be specifically determined to be applicable to the {E65 manufacture} and quality control of the relevant Miltenyi Product (if any) (for example, with regard to the {E66 manufacturing} of cell processing reagents or processing aids) by {E67 agreement} between Miltenyi and any relevant Regulatory Authority/ies and as set forth in Miltenyi's relevant Master Files and/or the Quality Agreement and (ii) any standard(s) as may be expressly agreed between the Parties with respect to a relevant Miltenyi Product from time to time in writing in this Agreement or in an {E68 amendment} to this Agreement. "Agreement" means this Supply Agreement, including Exhibits A, B, C, D, E, F and G attached hereto and incorporated herein, as amended from time to time in accordance with Section 20.3 hereof. "Applicable Laws" means all supranational, national, state and local laws, rules and regulations and guidelines governing the {E69 activities} of a Party described in this Agreement within the Territory that are applicable to the {E70 manufacture}, {E71 use}, {E72 storage}, {E73 import}, {E74 export} and {E75 handling} of the Miltenyi Products, including any applicable rules, regulations, guidelines, and other requirements of any Regulatory Authority that may be in effect in the Territory from time to time. "Bellicum Product" means one or more cell-based therapeutic product(s) that are manufactured using one or more Miltenyi Products and that are researched, developed and/or commercialized by or on behalf of Bellicum in the Field, as such products are identified in Modules set forth in Exhibit A to this Agreement, including related development candidate(s) and investigational cell-based therapeutics used under the sponsorship of Bellicum and as further specified in the applicable Module, as such Module may be amended from time to time by written notification of Bellicum to Miltenyi to add or remove product(s) in the Field. "Bellicum {E80 Program}" means a specific Bellicum {E76 program} for preclinical, clinical {E78 development} and/or {E79 commercialization} relating to one or more Bellicum Products as such {E80 program} is identified and described in a Module to this Agreement. "Business Day" means any  day  on which banking institutions in both San Francisco, US, and Bergisch Gladbach, Germany, are open for business. "Calendar Quarter" means each successive period of three consecutive calendar  months  commencing on  January 1 ,  April 1 ,  July 1  and  October 1 . "Calendar Year" means each successive period of twelve (12)  months  (each, a "Calendar Month") commencing on  January 1  and ending on  December 31 , except that the first Calendar Year shall be that period from and including the Effective  Date  through  December 31  of  that same year , and the last Calendar Year shall be that period from and including  the last January 1  of the  Term  through the earlier of the date of {E81 expiration} or {E82 termination} of this Agreement. "Clinical Grade Product" means any Miltenyi Product designated as "Clinical Grade" in the attached Exhibit B, Column "Quality Status". "Commercial Phase" means, on a Bellicum Product-by-Bellicum Product basis, the period of time during the  Term  of this Agreement following the {E83 approval} by the FDA or other applicable Regulatory Authorities in the Designated Countries for a particular Bellicum Product, during which period of time Bellicum desires Miltenyi to supply Bellicum, its Subcontractors and/or Licensees with Miltenyi Product(s). 1





Miltenyi Biotec-Bellicum Supply Agreement (Execution Copy,  March 27, 2019 )

"[...***...]" shall mean, with respect to the efforts and resources required to fulfill any obligation hereunder, the use of [...***...] of companies in the pharmaceutical industry or the biotech industry. "Communication" shall have the meaning set forth in Section 4.5. "Confidential Information" shall have the meaning set forth in Section 14. "Contract Year" means each successive period of twelve (12)-months during the  Term  ending on each anniversary of the Effective  Date  of this Agreement. "{E40 Delivery}" and " {E40 Deliver}  " shall have the meaning set forth in Section 6.1(a). " {E41 Designated}  Countries" means those countries listed under section "Designated Countries" on the Bellicum Product specific Module. "Discounts" shall have the meaning set forth in Section 8.4. "Ex Vivo Cell {E85 Processing}" means the {E86 selection}, {E87 modification}, {E88 alteration}, {E89 activation} and/or {E90 expansion} of cells outside the human body. "Facility" means (i) any production site owned or leased by Miltenyi or its Affiliate or by a Subcontractor of Miltenyi that is used for the {E91 manufacture} of the Miltenyi Products, and (ii) any warehouse or distribution facility of Miltenyi or its Affiliate or a Subcontractor of Miltenyi that holds or ships Miltenyi Products, as the case may be. "Field" means genetically modified, cell-based therapeutics for the {E92 treatment} of human diseases, including but not limited to {E93 treatment} of solid tumors and hematological cancers. "Firm Zone" shall have the meaning provided in Section 5.1(a). "Forecast" shall have the meaning provided in Article 5 of this Agreement. "Forecast Territory" means those countries where a particular Bellicum Product is manufactured, and for such {E94 manufacturing} where relevant Miltenyi Products are shipped, as listed under section "Forecast Territory" on the Bellicum Product specific Module. "Global Contract Number" means the reference number shown on the first page of this Agreement. "Initial  Term  " means the period set forth in Section 15.1. "Intellectual Property Rights" means any and all past, present, and future rights which exist, or which may exist or be created in the future, under the laws of any jurisdiction in the world with respect to all: (i) rights associated with works of authorship, including exclusive exploitation rights, copyrights, moral rights, and mask works; (ii) trademarks and trade name rights and similar rights; (iii) trade secret rights; (iv) inventions, patents, patent applications, and industrial property rights; (v) other proprietary rights in intellectual property of every kind and nature; and (vi) rights in or relating to {E95 registrations}, {E96 renewals}, {E97 re-examinations}, {E98 extensions}, {E99 combinations}, {E100 continuations}, {E101 divisions}, and {E102 reissues} of, and {E103 applications} for, any of the rights referred to in sub-clauses (i) through (v) above. 2





Miltenyi Biotec-Bellicum Supply Agreement (Execution Copy,  March 27, 2019 )

"Lead Time" means the minimum amount of time, as specified for each Miltenyi Product in Exhibit B hereto, between the date an applicable {E104 Purchase Order} (as defined below) for Miltenyi Product is received by Miltenyi and the requested date of {E105 Delivery}. "Licensee" means any Bellicum associated Third Party that has rights by way of license, sublicense, collaboration or otherwise to research, have researched, develop, have developed, make, have made, use, have used, sell, offer for {E106 sale}, import, have imported, export, have exported, or otherwise commercialize any Bellicum Product, as described in the Bellicum Product specific Module attached hereto as such Bellicum Product specific Module may be amended from time to time by written notification of Bellicum to Miltenyi to add or remove a Licensee. "Master File" means any Type II Master File, Medical Device Master File, or regulatory support file or other equivalent document, filed by or on behalf of Miltenyi, as of the Effective  Date  or during the  Term  , with the FDA, EMA and/or any other applicable Regulatory Authority that accepts such Master Files for any Miltenyi Products and/or any component thereof and/or any products used in connection therewith, as applicable, and in each case any amendment thereto. "Material {E108 Change}" means any {E108 change} to Agreed Standards, Product Specifications, critical raw materials, sources of critical raw materials and/or primary packaging of a Miltenyi Product that, to the extent reasonably foreseeable, could have potential adverse impact on the safety, quality, and/or {E109 performance} or could otherwise materially alter the properties of a Miltenyi Product. "Miltenyi Competitor" means the commercial entities and their respective Affiliates as set forth in Exhibit G attached hereto as such Exhibit G may be amended from time to time by written notification of Miltenyi to Bellicum of any {E112 proposal} to add or remove a Miltenyi Competitior, which {E141 addition} or {E142 removal} shall be mutually agreed by the Parties after good faith {E110 discussion} of such {E112 proposal}. "Miltenyi Products" means the products listed from time to time on Exhibit B attached hereto, and "Miltenyi Product" means any one of them. As  {E42 used}  herein, Miltenyi Products  {E43 include}  "Clinical Grade Products" and "Research Grade Products". "Miltenyi Product Warranty" shall have the meaning provided in Section 11.1. "Miltenyi Technology" means all Technology and Intellectual Property Rights  currently  in the possession of or controlled by Miltenyi, or conceived, developed or reduced to practice before or after the Effective  Date  by Miltenyi, relating to the {E113 research} and {E114 development}, {E115 manufacturing}, {E116 registration} for {E117 marketing}, {E118 handling}, {E119 use}, or {E120 sale} of a Miltenyi Product (e.g., instruments, columns, antibodies, antibody reagents, tubing sets, and buffers). The  term  "Miltenyi Technology"  {E44 includes}  the CliniMACSÂ® System, CliniMACSÂ® Prodigy System, the MACSÂ® Technology, and any other proprietary materials and methods useful for the {E121 selection}, {E122 activation}, {E123 purification}, {E124 cultivation}, or other kinds of {E125 processing}, of cells or biological materials, or products  {E45 utilizing}  any of the foregoing. "Module" means a written description, mutually agreed upon by the Parties, of one or more Bellicum Products or one or more Bellicum Program(s) under which Miltenyi agrees to supply Miltenyi Products to Bellicum under this Agreement, as specifically applicable for such Bellicum Product(s) or such Bellicum Program(s). Each Module shall be  {E46 agreed}  upon between the Parties on a Bellicum Product-by- Bellicum Product or Bellicum Program- by Bellicum-Program basis, as set forth in Section 1.4 and any amendment thereto. " Permitted  {E126 Use}" shall have the meaning provided in Section 2.2 hereof. 3





Miltenyi Biotec-Bellicum Supply Agreement (Execution Copy,  March 27, 2019 )

"Product Specifications" means the particulars as to composition, quality, safety, integrity, purity and other characteristics for a Miltenyi Product as published by Miltenyi from time to time, or as set forth in the applicable Quality Agreement entered into by the Parties in accordance with Section 3.2. " {E47 Purchase}  {E127 Order}" shall have the meaning set forth in Section 5.7. "Product Price" shall have the meaning set forth in Section 8.4. "Quality Agreement" means one or more written agreements between the Parties, incorporating all relevant quality assurance and quality control obligations and aspects for the Parties with respect to the supply of Clinical Grade Products to Bellicum by Miltenyi under this Agreement. "Regulatory Authority" means any federal, national, multinational, state, provincial or local regulatory agency, department, bureau or other governmental entity having the primary responsibility, jurisdiction, and authority to approve the {E128 manufacture}, {E129 use}, {E130 importation}, {E131 packaging}, {E132 labelling} and/or {E133 marketing} of pharmaceutical products or devices, including the United States Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"), and any equivalent or successor agency thereto. "Regulatory Work" shall have the meaning set forth in Section 4.3. "Rejected Products" shall have the meaning set forth in Section 7.2. "Renewal  Term  " shall have the meaning set forth in Section 15.1. "Required {E134 Change}" shall have the meaning set forth in Section 3.2(c). "Research Grade Product" means any Miltenyi Product designated as "Research Grade" in the attached Exhibit B, Column "Quality Status". "Subcontractor" means a Third Party to which, as applicable: (i) Miltenyi subcontracts the {E135 manufacture} and/or {E136 supply} of Miltenyi Products on behalf of Miltenyi and under Miltenyi's authority and responsibility in accordance with Section 2.5 and as further set forth in the Quality Agreement, if applicable; or (ii) Bellicum or its Licensees subcontracts the {E137 manufacture} and/or {E138 supply} of Bellicum Products on behalf of Bellicum or its Licensees and under Bellicum's or its Licensees' authority and responsibility in accordance with this Agreement and as described in the Bellicum Product specific Module attached hereto, as such Bellicum Product specific Module may be amended from time to time by written notification of Bellicum to Miltenyi to add or remove Subcontractor.




